NCT07138547View on ClinicalTrials.gov

GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2029

Conditions
Lymphoma
Interventions
DRUG

Eliglustat, CD30 target immunotherapy

"Eliglustat 63mg will be administered twice daily in the first 14 days and the following every other week.~CD30 target immunotherapy：Brentuximab Vedotin or CD30-targeting CAR-T Cell Therapy."

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER

NCT07138547 - GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma | Biotech Hunter | Biotech Hunter